Anterix Officer Sells $2.16M in Open Market After Option Exercise
ATEX has more than doubled off its 52-week low of $17.58.
Summary
Anterix's Chief Regulatory & Communications Officer sold $2.16 million in open market shares after exercising options, continuing a pattern of insider selling.
Key Events · Ownership and Investor Activity · ATEX
-
Officer Sells $2.16M in Open Market
Christopher Guttman-McCabe sold 23,439 shares at $90.61-$93.59 on 2026-08-25, generating $2,164,837 in proceeds.
-
Option Exercise at $34.72
Exercised 40,000 fully vested options at $34.72 per share, acquiring shares worth $1,388,800 at exercise price.
-
Tax Withholding of $1.5M
16,561 shares withheld at $90.38 per share ($1,496,783) to cover exercise price and tax obligations on a cashless basis.
-
Continuing Insider Distribution Pattern
This follows a $7.5M sale by the same officer on 2026-06-17; 90-day insider activity shows $28.6M in net selling with zero open market buys.
Analysis · ATEX · Technology
Chief Regulatory & Communications Officer Christopher Guttman-McCabe exercised 40,000 options at $34.72 and sold 23,439 shares on the open market for $2.16 million at prices between $90.61 and $93.59. This follows a $7.5 million sale by the same officer in June, continuing a pattern of insider distribution. The transaction represents 0.272% of market cap, which is notable for a mid-cap company. The sale was not part of a 10b5-1 plan, indicating a discretionary decision to monetize equity.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATEX was trading at $94.67 on NASDAQ in the Technology sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.58 to $113.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.